OLEMA PHARMACEUTICALS, INC. Stock-Based Compensation
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Stock-Based Compensation of $23.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $12.90M, a 175.00% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $10.15M, a 131.80% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $4.27M, a 32.53% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.25M, a 24.46% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $17.59M, a 22.12% decline from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $22.58M, a 30.86% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $17.26M, a 8.35% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $18.83M, a 18.32% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $23.05M 10-Q · filed 2026-08-10 | $27.32M derived: sum of 3 quarters · filed 2026-08-10 | $31.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $10.15M 10-Q · filed 2026-05-12 | $14.41M derived: sum of 2 quarters · filed 2026-05-12 | $18.66M derived: sum of 3 quarters · filed 2026-05-12 | $23.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.52M derived: sum of 2 quarters · filed 2026-03-16 | $13.21M derived: sum of 3 quarters · filed 2026-08-10 | $17.59M 10-K · filed 2026-03-16 |
| 2025-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.94M derived: sum of 2 quarters · filed 2026-08-10 | $13.32M 10-Q · filed 2025-11-10 | $19.64M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $9.07M 10-Q · filed 2026-08-10 | $15.39M derived: sum of 3 quarters · filed 2026-08-10 | $21.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $4.38M 10-Q · filed 2026-05-12 | $10.70M derived: sum of 2 quarters · filed 2026-05-12 | $16.33M derived: sum of 3 quarters · filed 2026-05-12 | $22.05M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $11.95M derived: sum of 2 quarters · filed 2026-03-16 | $17.67M derived: sum of 3 quarters · filed 2026-03-16 | $22.58M 10-K · filed 2026-03-16 |
| 2024-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.35M derived: sum of 2 quarters · filed 2025-11-10 | $16.26M 10-Q · filed 2025-11-10 | $20.61M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $5.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $10.63M 10-Q · filed 2025-08-11 | $14.98M derived: sum of 3 quarters · filed 2025-08-11 | $19.09M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $4.91M 10-Q · filed 2025-05-13 | $9.26M derived: sum of 2 quarters · filed 2025-05-13 | $13.37M derived: sum of 3 quarters · filed 2025-05-13 | $17.54M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $8.46M derived: sum of 2 quarters · filed 2025-03-18 | $12.63M derived: sum of 3 quarters · filed 2025-03-18 | $17.26M 10-K · filed 2025-03-18 |
| 2023-09-30 | $4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $8.28M derived: sum of 2 quarters · filed 2024-11-12 | $12.90M 10-Q · filed 2024-11-12 | $17.77M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $8.80M 10-Q · filed 2024-08-06 | $13.66M derived: sum of 3 quarters · filed 2024-08-06 | $17.94M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $4.63M 10-Q · filed 2024-05-08 | $9.49M derived: sum of 2 quarters · filed 2024-05-08 | $13.77M derived: sum of 3 quarters · filed 2024-05-08 | $18.49M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $9.14M derived: sum of 2 quarters · filed 2024-03-11 | $13.86M derived: sum of 3 quarters · filed 2024-03-11 | $18.83M 10-K · filed 2024-03-11 |
| 2022-09-30 | $4.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $9.00M derived: sum of 2 quarters · filed 2023-11-07 | $13.97M 10-Q · filed 2023-11-07 | $18.59M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $4.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.69M 10-Q · filed 2023-08-08 | $14.32M derived: sum of 3 quarters · filed 2023-08-08 | $18.48M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $4.96M 10-Q · filed 2023-05-09 | $9.59M derived: sum of 2 quarters · filed 2023-05-09 | $13.75M derived: sum of 3 quarters · filed 2023-05-09 | $17.67M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $8.78M derived: sum of 2 quarters · filed 2023-03-09 | $12.71M derived: sum of 3 quarters · filed 2023-03-09 | $15.91M 10-K · filed 2023-03-09 |
| 2021-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.08M derived: sum of 2 quarters · filed 2022-11-08 | $11.29M 10-Q · filed 2022-11-08 | $13.66M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $7.13M 10-Q · filed 2022-08-09 | $9.50M derived: sum of 3 quarters · filed 2022-08-09 | $10.08M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $3.21M 10-Q · filed 2022-05-09 | $5.58M derived: sum of 2 quarters · filed 2022-05-09 | $6.16M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.95M derived: sum of 2 quarters · filed 2022-02-28 | $3.11M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $582.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $736.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $154.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |